Synaptic Pharmaceutical Corporation

Janssen Pharmaceutica Nv

Janssen Pharmaceutica

George Chiu

Charles Gluchowski

John M Wetzel

Dhanapalan Nagarathnam

Wai C Wong

Peter J Connolly

Theresa A Branchek

Paul R Hartig

Carlos C Forray

Shengjian Li

Steven A Middleton

Mohammad R Marzabadi

Virginia L Pulito

Mohammed R Marzabadi

T G Murali Dhar

Ronghui Lin

Bharat Lagu

Shou Wu Miao

Jessica J Liu

Jingchun Liu

Stuart Emanuel

Shenlin Huang

T G Dhar

Yanhua Lu

Yang Yu

The present invention is directed to novel substituted pyrazole compounds of Formula (I) or a form or composition thereof and the use thereof as inhibitors of ATP-protein kinase interactions.

Substituted pyrazole kinase inhibitors

The present invention is directed to novel 3-benzoimidazolyl-pyrazolopyridine compounds of formula (I): and pharmaceutically acceptable forms thereof and their synthesis and use as inhibitors of serine-threonine protein kinases and tyrosine protein kinases and interactions thereof.

3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders

The present invention relates to substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds of Formula (I) and pharmaceutically acceptable forms thereof, as &#x3b1;/&#x3b1;adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods of treatment.

Substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds

The present invention relates to piperazine substituted cyclohexane-1,4-diamine compounds of Formula (I) and pharmaceutically acceptable forms thereof, as &#x3b1;/&#x3b1;adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods of treatment.

Piperazinyl substituted cyclohexane-1,4-diamines

The present invention relates to piperidine substituted cyclohexane-1,4-diamine compounds of Formula (I) and pharmaceutically acceptable forms thereof, as &#x3b1;/&#x3b1;adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as method of treatments.

Piperidinyl substituted cyclohexane-1,4-diamines

The present invention relates to substituted isoindole-1,3-dione compounds of Formula (I) and pharmaceutically acceptable forms thereof, as &#x3b1;/&#x3b1;adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods of treatment.

Substituted isoindole-1,3-diones

5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines

This invention provides dihydropyridines useful for treatment of prostatic hyperplasia, inhibition of cholesterol synthesis, and/or reduction of intraocular pressure.

Dihydropyridines and new uses thereof

A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human &agr; adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human &agr; adrenergic receptor, a human &agr; adrenergic receptor, and a human histamine H receptor, and, binds to a human &agr; adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such &agr; adrenergic receptor. Compounds meeting these criteria are provided.

Use of &agr;1C specific compounds to treat benign prostatic hyperplasia

The invention provides a method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound having the structure:

This invention is directed to dihydropyrimidine compounds of the following formula:

This invention is directed to the use of dihydropyrimidine compounds, which are selective antagonists for cloned human &agr;,receptors, for the treatment of benign prostatic hyperplasia and other diseases where antagonism of the human &agr;,receptor is useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-identified compounds and a pharmaceutically acceptable carrier.

Growing community of inventors

Bridgewater, NJ, United States of America

George Chiu